Song et al. suggested that the combination of immune-PET imaging and raidoimmunotherapy (RIT) agent, 64Cu/177Lu-PCTA-cetuximab, could facilitate target selection and targeted therapy via RIT in cetuximab-resistant HNSCC xenograft tumors expressing EGFR [27]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.